Immunotherapy Strategy Could Be Beneficial for Relapsed Acute …Newswise (press release)Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at… Continue reading
Study explores use of checkpoint inhibitors after relapse from donor stem cell transplantEurekAlert (press release)ATLANTA – Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who re… Continue reading
Study explores use of checkpoint inhibitors after relapse from donor stem cell transplantEurekAlert (press release)ATLANTA – Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who re… Continue reading
Medical Xpress |
Gene therapy improves immunity in babies with ‘bubble boy’ disease
Medical Xpress Ewelina Mamcarz, M.D., presents research at the 2017 ASH conference that indicates that the St. Jude XSCID gene therapy has been well tolerated and effective for infants as young as 2 months old. Credit: Peter Barta / St. Jude Children’s Research … |
Forbes |
Excitement Builds Around Gene Therapy Cures For Hemophilia
Forbes “The easiest thing to say is that we were absolutely blown away by them,” says K. John Pasi, of Barts Health NHS Trust and the London School of Medicine and Dentistry, who led the BioMarin study, of 9 patients. The patients all stopped using clotting … A 2nd Gene Therapy Breakthrough Against HemophiliaWebMD First Successful Gene Therapy for Hemophilia AMedPage Today BioMarin’s gene therapy reduces bleeding in hemophilia patientsSTAT BioPharma Dive –Healio –Markets Insider all 9 news articles » |
New Haven Register |
Yale doctor creates new weapons to kill cancer
New Haven Register “When you use the DNA approach, that DNA gets incorporated into your genome, whereas the RNA doesn’t change your genome at all,” Katz said. “It has some safety considerations.” There are several other advantages of using RNA, Katz said. It takes far … |